High-Energy Protocol Improves Photoaged Facial Skin

Share this content:
High-Energy Protocol Improves Photoaged Facial Skin
High-Energy Protocol Improves Photoaged Facial Skin

MONDAY, Feb. 13, 2017 (HealthDay News) -- For patients with mild-to-moderate facial wrinkles, a high-energy protocol with combined bipolar radiofrequency and infrared light energies improves facial skin, according to a study published online Feb. 8 in the Journal of Cosmetic Dermatology.

Michael H. Gold, M.D., from the Tennessee Clinical Research Center in Nashville, and colleagues examined a high-energy protocol with combined bipolar radiofrequency and infrared light energies for improving photoaged facial skin. Seventy-two patients with mild-to-moderate facial wrinkles underwent a single full-face treatment or two treatments (54 and 18 patients, respectively) at six-week intervals.

Following a single treatment or two treatments with the enhanced-energy protocol, the researchers found that all patients achieved some degree of improvement in their wrinkles and skin appearance. At the 12- and 24-week follow-ups after treatment, 71 and 70 percent of the patients, respectively, showed improvement of one unit of greater on the Fitzpatrick Scale. At six, 12, and 24 weeks after treatment end, 87, 91, and 81 percent of patients, respectively, showed improvement under the Global Aesthetic Improvement Scale. The treatments were well tolerated and patients were satisfied with the clinical results.

"The enhanced-energy treatment protocol, with fractional bipolar radiofrequency treatment and treatment with bipolar radiofrequency combined with infrared light applications, yields significant improvement of skin texture, wrinkling, and overall appearance following a single treatment," the authors write.

The study was funded by Syneron Candela.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »